2019 Nelson's Pediatric Antimicrobial Therapy

2019 Nelson's Pediatric Antimicrobial Therapy

by John S. Bradley

Paperback(New Edition)

$36.95
Choose Expedited Shipping at checkout for guaranteed delivery by Friday, March 29

Product Details

ISBN-13: 9781610022101
Publisher: American Academy of Pediatrics
Publication date: 01/01/2019
Edition description: New Edition
Pages: 316
Sales rank: 224,284
Product dimensions: 4.70(w) x 6.60(h) x 0.70(d)

About the Author

John S. Bradley, MD, is director of the Division of Infectious Diseases at the Children’s Hospital and Health Center, San Diego, and associate professor of pediatrics at the University of California, San Diego, School of Medicine.
 
John D. Nelson, MD, Emeritus, is professor emeritus of pediatrics at The University of Texas, Southwestern Medical Center at Dallas, Southwestern Medical School.

Elizabeth D. Barnett, MD is Professor of Pediatrics at Boston University School of Medicine and Attending Physician at Boston Medical Center where she is Director of the Refugee Health Assessment Program and the International Clinic. Her clinical and research interests are general pediatric infectious diseases, immigrant and refugee medicine, travel medicine, and vaccines and vaccine safety. She is a Site Director for GeoSentinel (a global surveillance network for travel and migration associated health issues).

Joseph B. Cantey, MD, is an Assistant Professor of Pediatrics at the University of Texas Health San Antonio. He attended medical school at the Medical University of South Carolina before completing his pediatric residency at Johns Hopkins. He then completed dual fellowships in pediatric infectious diseases and neonatal/perinatal medicine at the University of Texas Southwestern in Dallas, Texas. His research interests include antimicrobial stewardship and responsible prescribing in the nursery setting; infection control and prevention in the nursery setting; and the pathogenesis, diagnosis, treatment, and longitudinal follow-up of congenital and perinatal infections, particularly herpes simplex virus, cytomegalovirus, and syphilis.

David W. Kimberlin, MD, FAAP is the Principal Investigator for the Collaborative Antiviral Study Group (CASG), an international network of pediatric academic medical centers that evaluates antiviral therapeutics in rare diseases with a large unmet medical need, including neonatal herpes simplex virus (HSV) infections, congenital cytomegalovirus (CMV) disease, congenital Zika infection, neonatal and infantile influenza infection, and neonatal enteroviral sepsis syndrome. Studies conducted by the CASG have led to new drug indications and label changes for acyclovir, valganciclovir, and oseltamivir, and non-CASG studies conducted by Dr. Kimberlin also have led to label changes for valacyclovir.
 
Dr. Kimberlin is Editor of the 2018 AAP Report of the Committee on Infectious Diseases (Red Book). He also was Editor of the 2015 edition, and was an Associate Editor of the 2012 and 2009 editions. Dr. Kimberlin is a Past-President of the Pediatric Infectious Diseases Society (PIDS), which is the world's largest organization of professionals dedicated to the treatment, control, and eradication of infectious diseases affecting children. He also serves as Vice Chair for Clinical and Translational Research in the UAB Department of Pediatrics, where he holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases and is Co-Director of the Division of Pediatric Infectious Diseases.

Paul E. Palumbo, MD, is a subspecialist in Pediatric Infectious Diseases at Dartmouth Medical School.  He specializes in pediatric HIV and TB disease.

Jason Sauberan, PharmD, is research pharmacist, study coordinator, and investigator at the Neonatal Research Institute, Sharp Mary Birch Hospital for Women and Newborns in San Diego, CA.  He also performs clinical duties as a neonatal intensive care pharmacist and antibiotic stewardship pharmacist for the Sharp Mary Birch 84-bed level III NICU, and as a pediatric consultant pharmacist at the Helen Bernardy Center for Medically Fragile Children, Rady Children’s Hospital San Diego.  His research interests include anti-infection therapy, drugs in breast milk, parenteral nutrition, and medication safety. He serves on the Scientific Advisory Board of Mother to Baby California, and is an assistant clinical professor, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences.

J. Howard Smart, MD has been practicing General Pediatrics in San Diego since 1996, after completing his residency, which included working with Dr. Bradley at Children’s Hospital (now Rady’s). He is head of the Pediatrics department of his multi-specialty group, and teaches in the UCSD residents’ clinic. His involvement with Nelson’s started with a conversation with Dr. Bradley while flying to an AAP conference, discussing his hobby of mobile app development. Dr. Smart has been an app developer since 2011, and brings together the two knowledge domains of computer science and pediatrics in creating the mobile version of Nelson’s.

William J. Steinbach, MD is Professor of Pediatrics, Professor in Molecular Genetics and Microbiology, and Chief of Pediatric Infectious Diseases at Duke University. His expertise is in transplant infectious diseases, specifically in invasive fungal disease in children. He leads an integrated molecular, translational, and clinical research effort toward improving our understanding of invasive fungal disease epidemiology, diagnosis, and treatment.
 

Table of Contents


Introduction
Notable Changes to 2019 Nelson’s Pediatric Antimicrobial Therapy, 25th Edition
1.   Choosing Among Antibiotics Within a Class: Beta-lactams and Beta-lactamase Inhibitors, Macrolides, Aminoglycosides, and Fluoroquinolones
2.   Choosing Among Antifungal Agents: Polyenes, Azoles, and Echinocandins
3.   How Antibiotic Dosages Are Determined Using Susceptibility Data, Pharmacodynamics, and Treatment Outcomes
4.   Approach to Antibiotic Therapy of Drug-Resistant Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus
5.   Antimicrobial Therapy for Newborns
A.   Recommended Therapy for Selected Newborn Conditions
B.   Antimicrobial Dosages for Neonates
C.   Aminoglycosides
D.   Vancomycin
E.   Use of Antimicrobials During Pregnancy or Breastfeeding
6.   Antimicrobial Therapy According to Clinical Syndromes
A.   Skin and Soft Tissue Infections
B.   Skeletal Infections
C.   Eye Infections
D.   Ear and Sinus Infections
E.   Oropharyngeal Infections
F.   Lower Respiratory Tract Infections
G.   Cardiovascular Infections
H.   Gastrointestinal Infections
I.    Genital and Sexually Transmitted Infections
J.    Central Nervous System Infections
K.   Urinary Tract Infections
L.   Miscellaneous Systemic Infections
7.   Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens
A.   Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Positive)   
B.   Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Gram Negative)   
C.   Common Bacterial Pathogens and Usual Pattern of Susceptibility to Antibiotics (Anaerobes) 
D.   Preferred Therapy for Specific Bacterial and Mycobacterial Pathogens
8.   Preferred Therapy for Specific Fungal Pathogens
A.   Overview of More Common Fungal Pathogens and Their Usual Pattern of Antifungal Susceptibilities
B.   Systemic Infections
C.   Localized Mucocutaneous Infections
9.   Preferred Therapy for Specific Viral Pathogens
A.   Overview of Non-HIV, Non-Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals
B.   Overview of Hepatitis B or C Viral Pathogens and Usual Pattern of Susceptibility to Antivirals
C.   Preferred Therapy for Specific Viral Pathogens
10.   Preferred Therapy for Specific Parasitic Pathogens
A.   Selected Common Pathogenic Parasites and Suggested Agents for Treatment
B.   Preferred Therapy for Specific Parasitic Pathogens
11.   Alphabetic Listing of Antimicrobials
A.   Systemic Antimicrobials With Dosage Forms and Usual Dosages
B.   Topical Antimicrobials (Skin, Eye, Ear, Mucosa)
12.   Antibiotic Therapy for Children Who Are Obese
13.   Sequential Parenteral-Oral Antibiotic Therapy (Oral Step-down Therapy) for Serious Infections  
14.   Antimicrobial Prophylaxis/Prevention of Symptomatic Infection
A.   Postexposure Antimicrobial Prophylaxis to Prevent Infection
B.   Long-term Antimicrobial Prophylaxis to Prevent Symptomatic New Infection
C.   Prophylaxis of Symptomatic Disease in Children Who Have Asymptomatic Infection/Latent Infection
D.   Surgical/Procedure Prophylaxis
Appendix: Nomogram for Determining Body Surface Area
References
Index

 

Customer Reviews

Most Helpful Customer Reviews

See All Customer Reviews